DOI QR코드

DOI QR Code

Improved Detection of Metastases by Step Sectioning and Immuno-Histochemical Staining of Axillary Sentinel Nodes in Patients with Breast Carcinoma

  • Ensani, Fereshteh (Department of Pathology, Iran Cancer Institute, Emam Khomeini Hospital) ;
  • Enayati, Ladan (Department of Pathology, Iran Cancer Institute, Emam Khomeini Hospital) ;
  • Rajabiani, Afsaneh (Department of Pathology, Shariati Hospital, Tehran University of Medical Sciences) ;
  • Omranipour, Ramesh (Department of Pathology, Iran Cancer Institute, Emam Khomeini Hospital) ;
  • Alavi, Nasrinalsadat (Department of Surgery, Breast Cancer Research Center, Iranian Breast Cancer Research Center (IBCRC), Academic Center of Education Culture and Research (ACECR)) ;
  • Mosahebi, Sara (Department of Surgery, Breast Cancer Research Center, Iranian Breast Cancer Research Center (IBCRC), Academic Center of Education Culture and Research (ACECR))
  • Published : 2013.10.30

Abstract

Background: The object of this study was to examine whether a new protocol including step-sectioning and immunohistochemistry (IHC) staining of axillary sentinel nodes (SN) would lead to detection of more metastases in patients with breast cancer. Materials and Methods: Sixty-nine tumor free sentinel lymph nodes were examined. Step frozen sectioning was performed on formalin fixed SN and stained both by hematoxylin and eosin (H and E) and cytokeratin markers using IHC. Any tumoral cell in IHC stained slides were considered as a positive result. Metastases up to 0.2 mm were considered as isolated tumor cells and 0.2 up to 2 mm as micrometastasis. Results: Mean age of the patients was $48.7{\pm}12.2$ years. Step sectioning of the SN revealed 11 involved by metastasis which was statistically significant (p<0.001). Furthermore, 15 (21.7%) of the patients revealed positive results in IHC staining for pan-CK marker and this was also statistically significant (p=0.001). Ten patients had tumoral involvement in lymph nodes harvested from axillary dissection and 4 out of 15 lymph nodes with positive result for CK marker were isolated tumor cells. However, 4 of 10 patients with tumor positive lymph nodes in axillary dissection were negative for CK marker and in contrast 6 of the pan-CK positive SN were in patients with tumor-free axillary lymph nodes. Conclusions: Both IHC and step sectioning improve the detection rate of metastases. Considering the similar power of these two methods, we recommend using either IHC staining or step sectioning for better evaluation of harvested SNs.

Keywords

Breast cancer;sentinel node (SN) dissection;multilayer sectioning;immunohistochemistry

References

  1. Chagpar A, Middleton LP, Sahin AA et al (2005). Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer, 103, 1581-6. https://doi.org/10.1002/cncr.20934
  2. Czerniecki BJ, Scheff AM, Callans LS, et al (1999). Immunohistochemistry with pancytokeratins improves the sensitivity of sentinel lymph node biopsy in patients with breast carcinoma. Cancer, 85, 1098-103. https://doi.org/10.1002/(SICI)1097-0142(19990301)85:5<1098::AID-CNCR13>3.0.CO;2-N
  3. De Boer M, van Deurzen CH, van Dijck JA, et al (2009). Micrometastases or Isolated Tumor Cells and The Outcome of Breast Cance. N Eng J Med, 361, 653-63. https://doi.org/10.1056/NEJMoa0904832
  4. De Boer M, Van Dijck JAAM, Bult PGF, et al (2010). Tjan-Heijnen. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst, 102, 410-25. https://doi.org/10.1093/jnci/djq008
  5. Dowlatshahi K, Fan M, Bloom K, et al (1999). Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma. A Preliminary Study Cancer, 86, 990-6.
  6. Dowlatshahi K, Fan M, Snider HC, et al (1997). Lymph node micrometastases from breast carcinoma. Cancer, 80, 1188-97. https://doi.org/10.1002/(SICI)1097-0142(19971001)80:7<1188::AID-CNCR2>3.0.CO;2-H
  7. Freneaux PP, Nos C, Salomon AV, et al (2002). Histological Detection of Minimal Metastatic Involvement in Axillary Sentinel Nodes: A Rational Basis for a Sensitive Methodology Usable in Daily Practice. Mod Pathol, 15, 641-6. https://doi.org/10.1038/modpathol.3880580
  8. Hansen NM, Grube B, Ye X, Turner RR, et al (2009). Impact of micrometastases in sentinel lymph node of patients with invasive breast cancer. J cli oncol, 27, 4679-84. https://doi.org/10.1200/JCO.2008.19.0686
  9. Giuliano AE (1996). Sentinel lymphadenectomy in primary breast carcinoma: an alternative to routine axillary dissection. J Surg Oncol, 62, 75-6. https://doi.org/10.1002/(SICI)1096-9098(199606)62:2<75::AID-JSO1>3.0.CO;2-N
  10. Giuliano AE, Dale PS, Turner RR, et al (1995). Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg, 222, 394-401. https://doi.org/10.1097/00000658-199509000-00016
  11. Giuliano AE, Hunt KK, Ballman KV, et al (2011). Blumencranz, A. Marilyn leitch. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis a randomized clinical trial. JAMA, 305, 569-75. https://doi.org/10.1001/jama.2011.90
  12. Ivens D, Hoe AL, Podd TJ (1992). Assessment of morbidity from complete axillary dissection. Br J Cancer, 66, 136-8. https://doi.org/10.1038/bjc.1992.230
  13. Krag DN, Anderson SJ, Julian TB, et al (2010). Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol, 11, 927-33. https://doi.org/10.1016/S1470-2045(10)70207-2
  14. Langer G, Marti WR, Guller U, et al (2005). Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases. Ann Surg, 241, 152-8.
  15. Lucci A, McCall LM, Beitsch PD, et al (2007). American College of Surgeons Oncology Group. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group trial Z0011. J Clin Oncol, 25, 3657-63. https://doi.org/10.1200/JCO.2006.07.4062
  16. Pernas S, Gil M, Benitez A, et al (2010). Avoiding axillary treatment in sentinel lymph node micrometastasis of breast cancer: a prospective analysis of axillary or distant recurrence. Ann surg Oncol, 17, 772-7. https://doi.org/10.1245/s10434-009-0804-y
  17. Loya A, Guray M, Hennessy BT, et al (2009). Prognostic significance of occult axillary lymph node metastases after chemotherapy-induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Cancer, 115, 1605-12. https://doi.org/10.1002/cncr.24173
  18. Lyman GH, Giuliano AE, Somerfield MR, et al (2005). American society of clinical oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer 10. J Clin Oncol, 23, 7703-20. https://doi.org/10.1200/JCO.2005.08.001
  19. Ozcinar B, Muslumanoglu M, Igci A, et al (2011). Clinical significance of micrometastasis in sentinel lymph nodes. Breast, 20, 31-3. https://doi.org/10.1016/j.breast.2010.08.005
  20. Rubio IT, Korourian S, Cowan C, et al (1998). Sentinel lymph node biopsy for staging breast cancer. Am J Surg, 176, 532-7. https://doi.org/10.1016/S0002-9610(98)00264-5
  21. Ryde'n L, Chebil G, Sjostrom L, et al (2007). Determination of sentinel lymph node (SLN) status in primary breast cancer by prospective use of immunohistochemistry increases the rate of micrometastases and isolated tumour cells: Analysis of 174 patients after SLN biopsy. EJSO, 33, 33-8 https://doi.org/10.1016/j.ejso.2006.11.007
  22. Seung-Hye Choi SH, Barsky SH, Chang HR (2003). Clinicopathologic analysis of sentinel lymph node mapping in early breast cancer. Breast J, 9, 153-62. https://doi.org/10.1046/j.1524-4741.2003.09304.x
  23. Stitzenberg KB, Calvo BF, Iacocca MV, et al (2002). Cytokeratin immunohistochemical validation of the sentinel node hypothesis in patients with breast cancer. Am J Clin Pathol, 117, 729-37.
  24. Van Zee KJ, Manasseh D-ME, Bevilacqua JLB, et al (2003). A Nomogram for Predicting the Likelihood of Additional Nodal Metastases in Breast Cancer Patients With a Positive Sentinel Node Biopsy. Ann Surg Oncol, 10, 1140-51. https://doi.org/10.1245/ASO.2003.03.015
  25. Veronesi U, Paganelli G, Galimberti V et al (1997). Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet, 349, 1864-7. https://doi.org/10.1016/S0140-6736(97)01004-0
  26. Weaver DL, Krag DN, Ashikaga T, et al (2000). Pathologic analysis of sentinel and nonsentinel lymph nodes in breast carcinoma, a multicenter study. Cancer, 88, 1099-107. https://doi.org/10.1002/(SICI)1097-0142(20000301)88:5<1099::AID-CNCR22>3.0.CO;2-7
  27. Yeoh EK, Denham JW, Davies SA (1986). Primary breast cancer: complications of axillary management. Acta Radiol Oncol, 25, 105-8. https://doi.org/10.3109/02841868609136386

Cited by

  1. A Note of Caution vol.23, pp.7, 2015, https://doi.org/10.1177/1066896915596811
  2. Metastasis of Mammary Carcinoma in Bitches: Evaluation of the Sentinel Lymph Node Technique vol.05, pp.02, 2016, https://doi.org/10.4236/abcr.2016.52006
  3. Sentinel Node Biopsy Examination for Breast Cancer in a Routine Laboratory Practice: Results of a Pilot Study vol.17, pp.3, 2016, https://doi.org/10.7314/APJCP.2016.17.3.1149
  4. Biosensors for the Detection of Circulating Tumour Cells vol.14, pp.3, 2014, https://doi.org/10.3390/s140304856